Home / Intelligence

  • All
  • Blog
  • Briefs
  • Case Studies
  • Industry Publications
  • Podcasts
  • Scientific Publications
  • Webinars
  • White Papers

Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia

The purpose of this study was to systematically assess the prevalence, clinical consequences, and reporting of treatment-emergent hypophosphatemia within literature investigating IVI therapies marketed in the United States (US) Authors John Glaspy, Michelle Lim-Watson, Michael A Libre, Swagata Karkare, Nandini Hadker, Aleksandra Bajic-Lucas, William Strauss, Naomi Dahl Journal Therapeutics and Clinical Risk Management View publication…

Read Now

Evaluating the Ergonomic Outcomes of Digitally Assisted Vitreo-Retinal Surgery: A Systematic Literature Review

Recent developments in digitally assisted vitreo-retinal surgery (DAVS) and heads-up setup were introduced to the global ophthalmic surgical community to enhance visualization with digital signal amplification, higher resolution, and increased depth of field, while addressing some of the ergonomic challenges associated with conventional microscopes Authors Leighton Morris, William Wiley, Van Sandwick, Chiraag Lathia, Hang Cheng, Dina Abulon, Nandini Hadker, Kalin Hennegan Journal ISPOR EU 2020 View publication…

Read Now

Evaluating the Level of Endo-illumination Required during Digitally Assisted Vitreo-Retinal Surgery (DAVS): A Systematic Literature Review

While technological or procedural advances have resulted in low complication and re-operation rates, there are limitations of existing technologies — including but not limited to: surgical endo-illumination challenges, need for in-procedure adjustments, and additional information/support provided by other surgical devices — all of which can create challenges for surgeons during procedures Authors Leighton Morris, Alan Franklin, Van Sandwick, Chiraag Lathia, Hang Cheng, Nandini Hadker, Kalin Hennegan Journal ISPOR EU 2020 View publication…

Read Now

Is the Pricing Discount for Chinese NRDL Inclusion Worth it? NRDL Commercial Impact Assessment

July 06, 2021 Executive Summary The Chinese National Reimbursement Drug List (NRDL) is managed and negotiated by the National Healthcare Security Administration (NHSA) and drugs listed on the NRDL are reimbursed by the public insurance Since 2017, on average, a significant price discount of 44-61% was required for products to achieve a positive listing on the NRDL Based on average 2018 sales data, products included on the 2017 NRDL were able to achieve an increase in sales revenue (188%) despite…

Read Now

Poland’s Medical Fund Bill to Improve Access to Oncology Drugs

June 02, 2021 Executive Summary The Medical Fund Bill would increase drug spending up to 4% of the total healthcare spending in PolandThe reimbursement applications can be reviewed as quickly as 180 days, reducing the typical time-to-market of two – three yearsThe criteria for “innovativeness” that need to be met for inclusion on the list are still not fully fleshed out to dateOnly four of the 12 candidates on the list have been approved by the Health Minister to secure reimbursement…

Read Now

Novel Combinations: Double the Trouble

May 25, 2021 Executive Summary Branded novel combinations are increasingly entering the oncology market but bring a unique set of challenges to gain access and pricing successDynamics beyond demonstrating synergistic efficacy should be taken into consideration to optimize combination price / access outcomes Trinity’s Take: In this article, Trinity uses select combination case studies to highlight the key elements to consider when thinking through price / access strategy for a novel combination Evaluation of the Novel Combinations Landscape The pursuit of…

Read Now

How to Develop Strong Evidence to Enable Optimal Access Recording

Communicating a compelling value story to clinicians and payers is key to launching a product successfully and optimizing value throughout the product lifecycle. But how exactly does one generate evidence that will educate stakeholders on the disease state, shape the future market and support your value narrative?What are the ‘nuts and bolts’ of designing and conducting such studies?How do you distill down to the key value messages from a complex data set to be most impactful to clinical and payer…

Watch Now

Artificial Intelligence & Machine Learning in Pharma – Cutting Through the Hype Recording

There has been a lot of “buzz” around Artificial Intelligence & Machine Learning (AIML) in the pharma industry. But are companies really adopting it, and if so, how are they using it? TGaS Advisors, a division of Trinity Life Sciences, set out to separate fact from fiction while exploring these important questions in pharma commercial operations. Join us for an outside-in perspective as we share our findings after speaking with >100 commercial operations and analytics leaders from >50 life science…

Watch Now

Gender Equity in Commercial Executive Roles Recording

A diverse workforce signals competent management for investors and is a better reflection of your customers.” – VP, Commercial Operations TGaS Advisors, a division of Trinity Life Sciences, partnered with EMD Serono to develop Company and Pipeline Development Scorecards from a benchmark study of life sciences compared to ex-industry best practice research, including surveys/interviews with 23 unique life science companies in the TGaS Client Network. Join us to hear findings from the study. Key Webinar Topics Why and how does…

Watch Now

Sign up for the latest intelligence

By signing up, you are agreeing to our Privacy Policy.

By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email